Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02653014 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects and Subjects With Renal Impairment
A Phase 1 study, sponsored by KBP Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT02653014 is a Phase 1 study that has completed, run by KBP Biosciences. The registered enrollment target is 26 participants.
The verdict
NCT02653014, a Phase 1 study, has completed, sponsored by KBP Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
This multiple ascending dose (MAD) study in healthy subjects and subjects with mild to moderate renal impairment will evaluate the safety, tolerability and pharmacokinetics of KBP-5074. Safety/tolerability data and Pharmacokinetics (PK)/Pharmacodynamics (PD) (plasma aldosterone, serum potassium, UACR and Blood Pressure) relationships will be explored to support the selection of dosing regimens of KBP-5074 that are suitable for the Phase II/III study.
Interventions
- DRUG KBP-5074
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2015-07-29 |
| Est. Completion | 2017-03-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02653014
The ClinicalTrials.gov registry entry for NCT02653014 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is KBP Biosciences, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KBP-5074 is the first listed.
NCT02653014 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02653014 about?
NCT02653014 is a clinical study titled "Safety, Tolerability and Pharmacokinetics of KBP-5074 in Healthy Subjects and Subjects With Renal Impairment". This multiple ascending dose (MAD) study in healthy subjects and subjects with mild to moderate renal impairment will evaluate the safety, tolerability and pharmacokinetics of KBP-5074. Safety/tolerability data and Pharmacokinetics (PK)/Pharmacodynamics (PD) (plasma aldosterone, serum potassium, UAC...
What is the current status of trial NCT02653014?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2015-07-29. Estimated completion is 2017-03-28.
What interventions are being tested in trial NCT02653014?
The interventions under investigation include: KBP-5074 (DRUG).
Who is sponsoring clinical trial NCT02653014?
This trial is sponsored by KBP Biosciences, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.